Absci is trading 8.08% up at $9.58, with the move best explained by biotech-sector strength.
- No new company-specific announcement was identified on August 19, 2026.
- The latest investor-relations release, dated August 11, included positive ABS-201 Phase 1 data and a $100 million financing.
- XBI is up 3.73% amid a constructive market backdrop; the available earnings-call transcript does not explicitly attribute the gain to a company-specific catalyst.